• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The Characteristics of Treated Pulmonary Arterial Hypertension Patients in Ontario.安大略省接受治疗的肺动脉高压患者的特征
Can Respir J. 2016;2016:6279250. doi: 10.1155/2016/6279250. Epub 2016 Apr 11.
2
Treatment patterns and resource utilization and costs among patients with pulmonary arterial hypertension in the United States.美国肺动脉高压患者的治疗模式、资源利用和成本。
J Med Econ. 2010;13(3):393-402. doi: 10.3111/13696998.2010.496694.
3
Treatment patterns and healthcare system burden of managed care patients with suspected pulmonary arterial hypertension in the United States.美国疑似肺动脉高压的管理式医疗患者的治疗模式和医疗系统负担。
J Med Econ. 2012;15(5):947-55. doi: 10.3111/13696998.2012.690801. Epub 2012 May 22.
4
[Pharmacoeconomic aspects of macitentan in the therapy of pulmonary arterial hypertension].马昔腾坦治疗肺动脉高压的药物经济学方面
Ter Arkh. 2017;89(3):72-77. doi: 10.17116/terarkh201789372-77.
5
Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population.美国私人保险人群中肺动脉高压患者的额外费用。
Appl Health Econ Health Policy. 2011 Sep 1;9(5):293-303. doi: 10.2165/11592430-000000000-00000.
6
Characterizing pulmonary hypertension-related hospitalization costs among Medicare Advantage or commercially insured patients with pulmonary arterial hypertension: a retrospective database study.对医疗保险优势计划参保者或商业保险覆盖的肺动脉高压患者的肺动脉高压相关住院费用进行特征分析:一项回顾性数据库研究。
Am J Manag Care. 2015 Jan;21(3 Suppl):s47-58.
7
An international comparison of costs of end-of-life care for advanced lung cancer patients using health administrative data.利用卫生行政数据对晚期肺癌患者临终护理费用进行的国际比较。
Palliat Med. 2015 Dec;29(10):918-28. doi: 10.1177/0269216315596505. Epub 2015 Sep 1.
8
The cost to managed care of managing pulmonary hypertension.肺动脉高压管理的管理费用。
J Med Econ. 2012;15(3):500-8. doi: 10.3111/13696998.2012.665109. Epub 2012 Feb 22.
9
Parenteral Prostanoid Use at a Tertiary Referral Center: A Retrospective Cohort Study.三级转诊中心肠外前列腺素的使用:一项回顾性队列研究
Chest. 2016 Mar;149(3):660-6. doi: 10.1378/chest.15-1051. Epub 2016 Jan 6.
10
Healthcare resource utilization and costs for patients with pulmonary arterial hypertension: real-world documentation of functional class.肺动脉高压患者的医疗资源利用情况及费用:功能分级的真实记录
J Med Econ. 2017 Nov;20(11):1178-1186. doi: 10.1080/13696998.2017.1363049. Epub 2017 Aug 11.

引用本文的文献

1
Management of pulmonary hypertension in special conditions.特殊情况下肺动脉高压的治疗。
Eur Respir J. 2024 Oct 31;64(4). doi: 10.1183/13993003.01180-2024. Print 2024 Oct.
2
Prevalence, incidence, and survival of pulmonary arterial hypertension: A systematic review for the global burden of disease 2020 study.肺动脉高压的患病率、发病率和生存率:2020年全球疾病负担研究的系统评价
Pulm Circ. 2022 Jan 18;12(1):e12020. doi: 10.1002/pul2.12020. eCollection 2022 Jan.
3
Sex and gender in pulmonary arterial hypertension.肺动脉高压中的性别和性别差异。
Eur Respir Rev. 2021 Nov 8;30(162). doi: 10.1183/16000617.0330-2020. Print 2021 Dec 31.
4
Increasing Incidence and Prevalence of World Health Organization Groups 1 to 4 Pulmonary Hypertension: A Population-Based Cohort Study in Ontario, Canada.世界卫生组织1至4组肺动脉高压的发病率和患病率不断上升:加拿大安大略省的一项基于人群的队列研究。
Circ Cardiovasc Qual Outcomes. 2018 Feb;11(2):e003973. doi: 10.1161/CIRCOUTCOMES.117.003973.
5
Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States.美国肺动脉高压患者治疗开始前后的治疗模式及相关医疗保健费用。
J Manag Care Spec Pharm. 2018 Aug;24(8):834-842. doi: 10.18553/jmcp.2018.17391. Epub 2018 Feb 13.

本文引用的文献

1
Pulmonary arterial hypertension in adults: novel drugs and catheter ablation techniques show promise? Systematic review on pharmacotherapy and interventional strategies.成人肺动脉高压:新型药物与导管消融技术有望成功?药物治疗与介入策略的系统评价
Biomed Res Int. 2014;2014:743868. doi: 10.1155/2014/743868. Epub 2014 Jun 12.
2
Updated clinical classification of pulmonary hypertension.肺动脉高压的最新临床分类。
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D34-41. doi: 10.1016/j.jacc.2013.10.029.
3
Rates of hemorrhage during warfarin therapy for atrial fibrillation.华法林治疗心房颤动期间的出血率。
CMAJ. 2013 Feb 5;185(2):E121-7. doi: 10.1503/cmaj.121218. Epub 2012 Nov 26.
4
Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry.老年特发性肺动脉高压患者:COMPERA 注册研究结果。
Int J Cardiol. 2013 Sep 30;168(2):871-80. doi: 10.1016/j.ijcard.2012.10.026. Epub 2012 Nov 17.
5
Progression through diabetes therapies among new elderly users of metformin: a population-based study.新老年二甲双胍使用者的糖尿病治疗进展:一项基于人群的研究。
Diabet Med. 2013 Feb;30(2):e51-5. doi: 10.1111/dme.12049.
6
Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland.肺动脉高压英国和爱尔兰注册研究:发病肺动脉高压的人口统计学、流行病学和生存率变化。
Am J Respir Crit Care Med. 2012 Oct 15;186(8):790-6. doi: 10.1164/rccm.201203-0383OC. Epub 2012 Jul 12.
7
Incidence and significance of pericardial effusion in patients with pulmonary arterial hypertension.肺动脉高压患者心包积液的发生率及意义。
Can J Cardiol. 2013 Jun;29(6):678-82. doi: 10.1016/j.cjca.2012.04.009. Epub 2012 Jun 19.
8
Survival in pulmonary hypertension in Spain: insights from the Spanish registry.西班牙肺动脉高压患者的生存状况:来自西班牙注册研究的观察。
Eur Respir J. 2012 Sep;40(3):596-603. doi: 10.1183/09031936.00101211. Epub 2012 Feb 23.
9
An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry.从 REVEAL 注册研究评估肺动脉高压诊断后患者的长期生存。
Chest. 2012 Aug;142(2):448-456. doi: 10.1378/chest.11-1460.
10
Assessing response to therapy in idiopathic pulmonary arterial hypertension: a consensus survey of Canadian pulmonary hypertension physicians.评估特发性肺动脉高压治疗反应:加拿大肺动脉高压医生共识调查。
Can Respir J. 2011 Jul-Aug;18(4):230-4. doi: 10.1155/2011/510874.

安大略省接受治疗的肺动脉高压患者的特征

The Characteristics of Treated Pulmonary Arterial Hypertension Patients in Ontario.

作者信息

Vaid Haris M, Camacho Ximena, Granton John T, Mamdani Muhammad M, Yao Zhan, Singh Samantha, Juurlink David N, Gomes Tara

机构信息

School of Medicine, Queen's University, 15 Arch Street, Kingston, ON, Canada K7L 3N6.

The Institute for Clinical Evaluative Sciences, 2075 Bayview Avenue G1 06, Toronto, ON, Canada M4N 3M5.

出版信息

Can Respir J. 2016;2016:6279250. doi: 10.1155/2016/6279250. Epub 2016 Apr 11.

DOI:
10.1155/2016/6279250
PMID:27445555
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4904539/
Abstract

Background. There are no Canadian prevalence studies on pulmonary arterial hypertension (PAH) to date. We described the characteristics of treated PAH patients and the healthcare utilization and costs associated with PAH in a population of public drug plan beneficiaries in Ontario, Canada. Methods. A retrospective cross-sectional analysis was conducted between April 2010 and March 2011 to identify treated PAH patients using population-based health administrative databases. We investigated demographic and clinical characteristics of treated PAH patients and conducted a cohort study to determine treatment patterns, healthcare utilization, and associated costs, over a one-year follow-up period (March 2012). Results. We identified 326 treated PAH cases in Ontario's publicly funded drug plan. Overall mean age was 59.4 years (±20.3 years) and over 77% of cases were women (n = 251). Combination therapy was used to treat 22.9% (n = 69) of cases, costing an average of $4,569 (SD $1,544) per month. Median monthly healthcare costs were $264 (IQR $96-$747) for those who survived and $2,021 (IQR $993-$6,399) for those who died over a one-year period, respectively (p < 0.01). Conclusions. PAH care in Ontario is complex and has high healthcare costs. This data may help guide towards improved patient management.

摘要

背景。迄今为止,加拿大尚无关于肺动脉高压(PAH)的患病率研究。我们描述了加拿大安大略省公共药物计划受益人群中接受治疗的PAH患者的特征以及与PAH相关的医疗保健利用情况和费用。方法。在2010年4月至2011年3月期间进行了一项回顾性横断面分析,以使用基于人群的健康管理数据库识别接受治疗的PAH患者。我们调查了接受治疗的PAH患者的人口统计学和临床特征,并进行了一项队列研究,以确定在一年随访期(2012年3月)内的治疗模式、医疗保健利用情况和相关费用。结果。我们在安大略省的公共资助药物计划中识别出326例接受治疗的PAH病例。总体平均年龄为59.4岁(±20.3岁),超过77%的病例为女性(n = 251)。联合治疗用于治疗22.9%(n = 69)的病例,每月平均费用为4,569加元(标准差1,544加元)。在一年期间存活的患者每月医疗费用中位数为264加元(四分位间距96 - 747加元),死亡患者为2,021加元(四分位间距993 - 6,399加元),差异有统计学意义(p < 0.01)。结论。安大略省的PAH护理复杂且医疗费用高昂。这些数据可能有助于指导改善患者管理。